MedAlliance SELUTION SLR Receives Second FDA IDE Approval
GENEVA, Aug. 10, 2022 /PRNewswire/ — SELUTION SLR™, MedAlliance’s novel sirolimus-eluting balloon, has received conditional FDA Investigational Device Exemption (IDE) approval
Read MoreGENEVA, Aug. 10, 2022 /PRNewswire/ — SELUTION SLR™, MedAlliance’s novel sirolimus-eluting balloon, has received conditional FDA Investigational Device Exemption (IDE) approval
Read MoreLEIPZIG, Germany, June 8, 2022 /PRNewswire/ — The first patient has been enrolled in the FDA IDE BTK (Below-the-Knee) SELUTION4BTK
Read MoreGENEVA, May 30, 2022 /PRNewswire/ — The SELUTION SLR (Sustained Limus Release) is a novel sirolimus-eluting balloon that provides a
Read More